logo-loader
viewScancell Holdings PLC

New Scancell chief sets out his vision to commercialise groundbreaking cancer treatments

Cliff Holloway, chief executive of Scancell Holdings Plc (LON:SCLP), spoke to Proactive soon after taking over as CEO at the immuno-oncology company.

Holloway says generating clinical data's a big focus for them in the near-term.

''Over the next two years we expect to see clinical readouts from two of our programmes - SCIB1 and Modi-1''.

''We'll be extending our pipeline particularly around Moditope with the Modi-3 programme, if we're successful with the grand challenge''.

''Then it's around looking at technical partnerships that will allow us to de-risk our developments''.

Quick facts: Scancell Holdings PLC

Price: 6 GBX

LSE:SCLP
Market: LSE
Market Cap: £27.92 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Scancell Holdings PLC named herein, including the promotion by the Company of Scancell Holdings PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Scancell Holdings CEO discusses new research programme into coronavirus vaccine

Scancell Holdings PLC's (LON:SCLP) Cliff Holloway speaks to Proactive London's Andrew Scott after revealing it's begun a research programme to develop a vaccine for the coronavirus. The project, to be led by the company’s chief scientific officer Lindy Durrant, will aim to use the company’s...

on 24/4/20

2 min read